Skip to content

Celyad Oncology

Active
Public limited companyfounded 200719 yrs activeRue Emile Francqui 6, 1435 Mont-Saint-Guibert, BelgiumKBO/BCE: BE 0891.118.115
Summary

Celyad Oncology has been active since 2007 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.24M and a net result of €-565k. Equity is shrinking by ~45.6% per year across the filed fiscal years. Its solvency ranks better than 54% of 191 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).

Risk analysis Watch Report Compare
Celyad OncologyActiveChecked score 66/100
Risk analysis Report Compare

Checked score

Score 2025
66 / 100
Healthy
Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability1▲+1
Solvency81▲+36
Growth38=
Track record100
Bankruptcy probability, 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2k at 30 days acceptable
Liquidity ample (current ratio 2.32 against 2.92 in 2024; short-term debt: 41.5% and cash: 40.5% of total assets), and 44.5% of the assets are financed with debt.
Credit check for your own amount and term

Signals

Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 19 years 0 20 y
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
55.5%
Return on assets
-14%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-06-2026, 51 days ahead of the deadline.
NBB · 6 filings
Deviation from the deadline
2025
51 d early
2024
71 d early
2023
64 d early
2022
56 d early
2021
68 d early
2020
67 d early
← before the deadline after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
25-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

Financials · fiscal year 2025, full schema, statutory accounts

Turnover
€21k▼ 88.7%
2024 · €186k
2018: €1.57Mhighest value 2019: €6k▼ -99.6% vs 2018 2020: €5k▼ -25.1% vs 2019lowest value 2022: €1.31M 2023: €103k▼ -92.2% vs 2022 2024: €186k▲ +80.3% vs 2023 2025: €21k▼ -88.7% vs 2024
2018 → 2025
EBIT margin
-2858.4%▲ 725.3pp
2024 · -3583.7%
2018: -2158.3%highest value 2019: -489075.2%▼ -22560% vs 2018 2020: -563882.5%▼ -15.3% vs 2019lowest value 2022: -3014.4% 2023: -9269.3%▼ -208% vs 2022 2024: -3583.7%▲ +61.3% vs 2023 2025: -2858.4%▲ +20.2% vs 2024
2018 → 2025
Net result
€-565k▲ 91.2%
2024 · €-6.41M
2018: €-30.73M 2019: €-28.08M▲ +8.6% vs 2018 2020: €-26.76M▲ +4.7% vs 2019 2021: €-29.46M▼ -10.1% vs 2020 2022: €-39.62M▼ -34.5% vs 2021lowest in 8 years 2023: €-24.73M▲ +37.6% vs 2022 2024: €-6.41M▲ +74.1% vs 2023 2025: €-565k▲ +91.2% vs 2024highest in 8 years
2018 → 2025
Working capital
€2.21M▼ 57.7%
2024 · €5.23M
2018: €45.27Mhighest in 8 years 2019: €37.29M▼ -17.6% vs 2018 2020: €15.56M▼ -58.3% vs 2019 2021: €25.31M▲ +62.7% vs 2020 2022: €10.35M▼ -59.1% vs 2021 2023: €11.47M▲ +10.8% vs 2022 2024: €5.23M▼ -54.4% vs 2023 2025: €2.21M▼ -57.7% vs 2024lowest in 8 years
2018 → 2025
Trend over the years
Multi-year overview
Every figure with its change against the year before
▲ rise ▼ fall
Line20212022202320242025Trend
Turnover€1.31M€103k▼ 92.2%€186k▲ 80.3%€21k▼ 88.7% 2022: €1.31Mhighest in 4 years 2023: €103k▼ -92.2% vs 2022 2024: €186k▲ +80.3% vs 2023 2025: €21k▼ -88.7% vs 2024lowest in 4 years
Equity€62.78M-€23.15M▼ 63.1%€8.22M▼ 64.5%€1.80M▼ 78.0%€2.24M▲ 24.1% 2021: €62.78Mhighest in 5 years 2022: €23.15M▼ -63.1% vs 2021 2023: €8.22M▼ -64.5% vs 2022 2024: €1.80M▼ -78.0% vs 2023lowest in 5 years 2025: €2.24M▲ +24.1% vs 2024
Operating result€-28.99M-€-39.62M▼ 36.7%€-9.54M▲ 75.9%€-6.65M▲ 30.3%€-600k▲ 91.0% 2021: €-28.99M 2022: €-39.62M▼ -36.7% vs 2021lowest in 5 years 2023: €-9.54M▲ +75.9% vs 2022 2024: €-6.65M▲ +30.3% vs 2023 2025: €-600k▲ +91.0% vs 2024highest in 5 years
Net result€-29.46M-€-39.62M▼ 34.5%€-24.73M▲ 37.6%€-6.41M▲ 74.1%€-565k▲ 91.2% 2021: €-29.46M 2022: €-39.62M▼ -34.5% vs 2021lowest in 5 years 2023: €-24.73M▲ +37.6% vs 2022 2024: €-6.41M▲ +74.1% vs 2023 2025: €-565k▲ +91.2% vs 2024highest in 5 years
Result per fiscal year
Operating resultNet result
€-40.00M€-30.00M€-20.00M€-10.00M€0Operating result 2021: €-28.99M€-28.99MNet result 2021: €-29.46M€-29.46MOperating result 2022: €-39.62M€-39.62MNet result 2022: €-39.62M€-39.62MOperating result 2023: €-9.54M€-9.54MNet result 2023: €-24.73M€-24.73MOperating result 2024: €-6.65M€-6.65MNet result 2024: €-6.41M€-6.41MOperating result 2025: €-600k€-600kNet result 2025: €-565k€-565k20212022202320242025€-30M€-20M€-10M€0Operating result 2023: €-9.54M€-9.5MNet result 2023: €-24.73M€-25MOperating result 2024: €-6.65M€-6.6MNet result 2024: €-6.41M€-6.4MOperating result 2025: €-600k€-600kNet result 2025: €-565k€-565k202320242025
The operating result stays negative: a loss of €600k in 2025 against €6.65M in 2024; the loss shrinks.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €4.03M
Fixed assets €150k ▼ 84.4%
Current assets €3.88M ▼ 51.1%
Equity and liabilities €4.03M
Equity €2.24M ▲ 24.1%
Provisions €77k
Debt €1.72M ▼ 75.8%
Debt's share of the balance-sheet total falls from 79.7% to 42.6%. Equity is higher and debt is lower.
Key figures and ratios
2025 value · change against 2024
EBITDA
€-552k▲
2024 · €-4.29M
Cash flow
€-516k▲
2024 · €-4.05M
Current ratio
2.32▼
2024 · 2.92
Quick ratio
2.11▼
2024 · 2.77
Debt to equity
0.77▼
2024 · 3.94
ROE
-25.2%▲
2024 · -355.4%
ROA
-14.0%▲
2024 · -72.0%
Interest coverage
-1201.28▲
2024 · -4523.86
Debt ≤ 1 year
€1.67M▼
2024 · €2.72M
Debt > 1 year
€43k▼
2024 · €4.38M
Income taxes
€835▲
2024 · €-200k
Staff costs
€2.76M▲
2024 · €2.18M
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 87 lines
Balance sheet Code20242025
Assets
Total assets20/58€8.91M€4.03M▼
Fixed assets21/28€959k€150k▼
Intangible fixed assets21€129k€109k▼
Tangible fixed assets22/27€727k-
Plant, machinery and equipment23€115k-
Furniture and vehicles24€42k-
Leasing and similar rights25€23k-
Other tangible fixed assets26€547k-
Financial fixed assets28€103k€41k▼
Affiliated companies280/1€7k€7k=
Participating interests280€7k€7k=
Other financial fixed assets284/8€95k€33k▼
Amounts receivable and cash guarantees285/8€95k€33k▼
Current assets29/58€7.95M€3.88M▼
Amounts receivable after more than one year29€1.46M€783k▼
Other amounts receivable291€1.46M€783k▼
Stocks and contracts in progress3€417k€352k▼
Stocks30/36€417k€352k▼
Finished goods33€151k€55k▼
Advance payments36€266k€297k▲
Amounts receivable within one year40/41€950k€853k▼
Trade receivables40€170k€72k▼
Other amounts receivable41€780k€781k▲
Current investments50/53€2.00M-
Other investments51/53€2.00M-
Cash at bank and in hand54/58€2.18M€1.64M▼
Deferred charges and accrued income490/1€946k€261k▼
Equity and liabilities
Total equity and liabilities10/49€8.91M€4.03M▼
Equity10/15€1.80M€2.24M▲
Contributions10/11€8.22M€9.22M▲
Capital10€8.22M€9.22M▲
Issued capital100€8.22M€9.22M▲
Profit (loss) carried forward14€-6.41M€-6.98M▼
Provisions and deferred taxes16-€77k
Provisions for liabilities and charges160/5-€77k
Other liabilities and charges164/5-€77k
Amounts payable17/49€7.10M€1.72M▼
Amounts payable after more than one year17€4.38M€43k▼
Financial debts170/4€4.32M-
Leasing and similar obligations172€9k-
Other loans174€4.32M-
Other amounts payable178/9€58k€43k▼
Amounts payable within one year42/48€2.72M€1.67M▼
Current portion of amounts payable after more than one year42€739k€621k▼
Trade debts44€1.32M€770k▼
Suppliers440/4€1.32M€770k▼
Advances received on contracts in progress46€46k€25k▼
Taxes, remuneration and social security45€407k€141k▼
Taxes450/3€31k€24k▼
Remuneration and social security454/9€376k€116k▼
Other amounts payable47/48€206k€118k▼
Accrued charges and deferred income492/3€0-
Income statement Code20242025
Operating income70/76A€3.24M€7.27M▲
Turnover70€186k€21k▼
Change in stocks of work in progress, finished goods and contracts in progress71€151k€-96k▼
Own construction capitalised72€2.26M-
Other operating income74€648k€701k▲
Non-recurring operating income76A€569€6.65M▲
Operating charges60/66A€9.89M€7.87M▼
Goods for resale, raw materials and consumables60€481k€142k▼
Purchases600/8€481k€142k▼
Services and other goods61€4.17M€4.71M▲
Remuneration, social security and pensions62€2.18M€2.76M▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€2.36M€48k▼
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4-€-250k
Provisions for liabilities and charges: additions (uses and reversals)635/8-€77k
Other operating charges640/8€700k€380k▼
Non-recurring operating charges66A€100€12k▲
Operating profit (loss)9901€-6.65M€-600k▲
Financial income75/76B€163k€62k▼
Recurring financial income75€163k€62k▼
Income from current assets751€153k€12k▼
Other financial income752/9€10k€50k▲
Financial charges65/66B€127k€26k▼
Recurring financial charges65€52k€26k▼
Debt charges650€948€459▼
Other financial charges652/9€51k€25k▼
Non-recurring financial charges66B€75k-
Profit (loss) for the period before taxes9903€-6.61M€-564k▲
Income taxes67/77€-200k€835▲
Taxes670/3€4k€12k▲
Tax adjustments and reversals of tax provisions77€205k€11k▼
Profit (loss) for the period9904€-6.41M€-565k▲
Profit (loss) for the period to be appropriated9905€-6.41M€-565k▲
Appropriation of the result
Profit (loss) to be appropriated9906€-6.41M€-6.98M▼
Profit (loss) brought forward from the previous period14P-€-6.41M
Social balance
Average headcount (FTE)908715.610.5▼

The notes to these accounts (78 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Accounts by statement
Line20212022202320242025Change
Operating income70/76A€27.79M€24.81M€7.88M€3.24M€7.27M▲ 124%
Turnover70-€1.31M€103k€186k€21k▼ 88.7%
Change in stocks of work in progress, finished goods and contracts in progress71---€151k€-96k▼ 163%
Own construction capitalised72€20.34M€13.91M€4.42M€2.26M--
Other operating income74€7.44M€4.35M€2.07M€648k€701k▲ 8.3%
Non-recurring operating income76A€607€5.24M€1.28M€569€6.65M▲ 1,168,008%
Operating charges60/66A€56.78M€64.43M€17.42M€9.89M€7.87M▼ 20.4%
Goods for resale, raw materials and consumables60€3.34M€1.38M€257k€481k€142k▼ 70.4%
Purchases600/8€3.34M€1.38M€257k€481k€142k▼ 70.4%
Services and other goods61€18.57M€14.33M€8.73M€4.17M€4.71M▲ 12.9%
Remuneration, social security and pensions62€9.15M€8.08M€2.74M€2.18M€2.76M▲ 26.4%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€24.57M€17.83M€4.53M€2.36M€48k▼ 97.9%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4-€132k€125k-€-250k-
Provisions for liabilities and charges: additions (uses and reversals)635/8----€77k-
Other operating charges640/8€1.15M€2.19M€1.02M€700k€380k▼ 45.7%
Non-recurring operating charges66A€172€20.48M€13k€100€12k▲ 11,523%
Operating profit (loss)9901€-28.99M€-39.62M€-9.54M€-6.65M€-600k▲ 91.0%
Financial income75/76B€920k€939k€199k€163k€62k▼ 61.9%
Recurring financial income75€920k€939k€199k€163k€62k▼ 61.9%
Income from financial fixed assets750€0-----
Income from current assets751€639€717€30k€153k€12k▼ 92.4%
Other financial income752/9€920k€938k€169k€10k€50k▲ 412%
Financial charges65/66B€240k€1.40M€15.54M€127k€26k▼ 79.6%
Recurring financial charges65€240k€374k€666k€52k€26k▼ 50.6%
Debt charges650€3k€2k€2k€948€459▼ 51.5%
Other financial charges652/9€236k€372k€665k€51k€25k▼ 50.6%
Non-recurring financial charges66B-€1.03M€14.87M€75k--
Profit (loss) for the period before taxes9903€-28.31M€-40.08M€-24.88M€-6.61M€-564k▲ 91.5%
Income taxes67/77€1.15M€-457k€-144k€-200k€835▲ 100%
Taxes670/3€1.85M€6k€5k€4k€12k▲ 192%
Tax adjustments and reversals of tax provisions77€692k€462k€149k€205k€11k▼ 94.5%
Profit (loss) for the period9904€-29.46M€-39.62M€-24.73M€-6.41M€-565k▲ 91.2%
Profit (loss) for the period to be appropriated9905€-29.46M€-39.62M€-24.73M€-6.41M€-565k▲ 91.2%
Line20212022202320242025Change
Assets
Total assets20/58€77.05M€34.48M€14.99M€8.91M€4.03M▼ 54.7%
Fixed assets21/28€39.51M€16.55M€1.11M€959k€150k▼ 84.4%
Intangible fixed assets21€24.45M-€30k€129k€109k▼ 15.9%
Tangible fixed assets22/27€940k€431k€935k€727k--
Plant, machinery and equipment23€272k€49k€188k€115k--
Furniture and vehicles24€76k€43k€67k€42k--
Leasing and similar rights25€139k€100k€61k€23k--
Other tangible fixed assets26€453k€239k€619k€547k--
Financial fixed assets28€14.12M€16.12M€145k€103k€41k▼ 60.2%
Affiliated companies280/1€13.86M€15.85M€7k€7k€7k=
Participating interests280€2.13M€1.10M€7k€7k€7k=
Amounts receivable281€11.73M€14.75M----
Other financial fixed assets284/8€259k€262k€137k€95k€33k▼ 64.9%
Amounts receivable and cash guarantees285/8€259k€262k€137k€95k€33k▼ 64.9%
Current assets29/58€37.53M€17.94M€13.88M€7.95M€3.88M▼ 51.1%
Amounts receivable after more than one year29€5.21M€4.89M€2.78M€1.46M€783k▼ 46.3%
Other amounts receivable291€5.21M€4.89M€2.78M€1.46M€783k▼ 46.3%
Stocks and contracts in progress3---€417k€352k▼ 15.6%
Stocks30/36---€417k€352k▼ 15.6%
Finished goods33---€151k€55k▼ 63.4%
Advance payments36---€266k€297k▲ 11.6%
Amounts receivable within one year40/41€2.39M€1.45M€2.85M€950k€853k▼ 10.3%
Trade receivables40€475k€1.10M€457k€170k€72k▼ 58.0%
Other amounts receivable41€1.92M€351k€2.39M€780k€781k▲ 0.2%
Current investments50/53--€4.00M€2.00M--
Other investments51/53--€4.00M€2.00M--
Cash at bank and in hand54/58€28.97M€11.03M€3.00M€2.18M€1.64M▼ 24.8%
Deferred charges and accrued income490/1€965k€562k€1.26M€946k€261k▼ 72.4%
Equity and liabilities
Total equity and liabilities10/49€77.05M€34.48M€14.99M€8.91M€4.03M▼ 54.7%
Equity10/15€62.78M€23.15M€8.22M€1.80M€2.24M▲ 24.1%
Contributions10/11€92.24M€92.24M€32.95M€8.22M€9.22M▲ 12.2%
Capital10€78.58M€78.58M€32.95M€8.22M€9.22M▲ 12.2%
Issued capital100€78.58M€78.58M€32.95M€8.22M€9.22M▲ 12.2%
Outside capital11€13.65M€13.65M----
Share premium1100/10€13.65M€13.65M----
Profit (loss) carried forward14€-29.46M€-69.08M€-24.73M€-6.41M€-6.98M▼ 8.8%
Provisions and deferred taxes16----€77k-
Provisions for liabilities and charges160/5----€77k-
Other liabilities and charges164/5----€77k-
Amounts payable17/49€14.27M€11.33M€6.78M€7.10M€1.72M▼ 75.8%
Amounts payable after more than one year17€2.05M€3.55M€4.14M€4.38M€43k▼ 99.0%
Financial debts170/4€1.83M€3.38M€4.03M€4.32M--
Leasing and similar obligations172€125k€87k€48k€9k--
Other loans174€1.71M€3.29M€3.98M€4.32M--
Other amounts payable178/9€212k€168k€109k€58k€43k▼ 26.1%
Amounts payable within one year42/48€12.22M€7.58M€2.41M€2.72M€1.67M▼ 38.4%
Current portion of amounts payable after more than one year42€253k€404k€389k€739k€621k▼ 15.9%
Trade debts44€6.72M€4.72M€1.23M€1.32M€770k▼ 41.8%
Suppliers440/4€6.72M€4.72M€1.23M€1.32M€770k▼ 41.8%
Advances received on contracts in progress46---€46k€25k▼ 46.2%
Taxes, remuneration and social security45€4.10M€1.45M€549k€407k€141k▼ 65.5%
Taxes450/3€2.26M€325k€53k€31k€24k▼ 21.9%
Remuneration and social security454/9€1.84M€1.13M€496k€376k€116k▼ 69.1%
Other amounts payable47/48€1.15M€1.00M€243k€206k€118k▼ 42.7%
Accrued charges and deferred income492/3€1€200k€231k€0--
Line20212022202320242025Change
Profit (loss) for the period9904€-29.46M€-39.62M€-24.73M€-6.41M€-565k▲ 91.2%
+ Depreciation and write-downs630€24.57M€17.83M€4.53M€2.36M€48k▼ 97.9%
Operating cash flow (approximation)€-4.89M€-21.80M€-20.20M€-4.05M€-516k▲ 87.2%
Investment in fixed assets (approximation)-€5.14M€10.91M€-2.21M€761k▲ 134%
Change in cash-€-17.94M€-8.03M€-822k€-540k▲ 34.3%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Sign in to download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
31-07
State Gazette act Capital & shares · Statutes amendment
Capital increase · Capital4 facts ▸
  • Board meeting, 16/07/2026
  • Capital increase, €500.000
  • Capital, €9.716.154,53
  • Statutes amendment
10-06
NBB filing Annual accounts filed
fiscal year 2025 · full schema
12-03
State Gazette act Resignation: Ami Patel Shah (director)
Power of attorney3 facts ▸
  • Board meeting, 06/02/2026
  • Director resignation, Ami Patel Shah (director)
  • Power of attorney, Adrien Lanotte
30-01
State Gazette act Resignation: Matthew Kane (délégué à la gestion journalière/ceo)
2 facts ▸
  • Board meeting, 04/12/2025
  • Director resignation, Matthew Kane (délégué à la gestion journalière/ceo)
2025
31-12
Financial Equity above €2MEq €2.24M ▲24.1%
Equity rises from €1.80M to €2.24M.
29-12
State Gazette act Appointment: Resilient ID, SRL (délégué à la gestion journalière / directeur général)
2 facts ▸
  • Board meeting, 04/11/2025
  • Director appointment, Resilient ID, SRL (délégué à la gestion journalière / directeur général)
31-10
State Gazette act Resignation: Andrea Gothing (director)
Appointment: Sharon Roberg-Perez (director) · Power of attorney7 facts ▸
  • Board meeting, 24/09/2025
  • Director resignation, Andrea Gothing (director)
  • Director appointment, Sharon Roberg-Perez (director)
  • Power of attorney, An Phan
  • Power of attorney, F&C Consulting SRL
  • Power of attorney, Adrien Lanotte
  • Power of attorney, Harvest Avocats
15-10
State Gazette act Registered office
Registered-office move2 facts ▸
  • Board meeting, 24/09/2025
  • Registered-office move, 6 rue Emile Francqui à 1435 Mont Saint Guibert
21-08
State Gazette act Capital & shares · Statutes amendment
Capital increase · Capital · Pre-emptive rights6 facts ▸
  • Board meeting, 05/08/2025
  • Capital increase, €999.999,9
  • Capital, €9.216.154,53
  • Statutes amendment
  • Pre-emptive rights, supprimé
  • Profit participation from, 01/01/2025
16-06
State Gazette act Reappointment: Marina Udier Blagovic (director)
2 facts ▸
  • General meeting, 20/05/2025
  • Director reappointment, Marina Udier Blagovic (director)
22-05
NBB filing Annual accounts filed
fiscal year 2024 · consolidated
21-05
NBB filing Annual accounts filed
fiscal year 2024 · full schema
Show earlier events
2024
05-12
State Gazette act Appointment: KANE Matthew Roy (director)
Statutes amendment · Mandate compensation4 facts ▸
  • General meeting, 02/12/2024
  • Statutes amendment
  • Director appointment, KANE Matthew Roy (director)
  • Mandate compensation, KANE Matthew Roy
20-11
State Gazette act Resignation: Mel Management srl (délégué à la gestion journalière ad interim)
2 facts ▸
  • Board meeting, 12/09/2024
  • Director resignation, Mel Management srl (délégué à la gestion journalière ad interim)
11-10
State Gazette act Appointment: Matthew Kane (daily management delegate)
2 facts ▸
  • Board meeting, 12/09/2024
  • Director appointment, Matthew Kane (daily management delegate)
03-10
State Gazette act Miscellaneous
Share issue · Capital increase · Waiver of preemptive rights6 facts ▸
  • Board meeting, 30/09/2024
  • Share issue, droits de souscription, 1315000
  • Capital increase
  • Waiver of preemptive rights, article 7 des statuts et article 7:191 CSA, membres du personnel de la Société
  • Board powers, détermination des bénéficiaires, offre des droits, collecte de l'acceptation, fixation du prix d'exercice
  • Document deposit
18-06
State Gazette act Reappointments: Dominic Piscitelli, Serge Goblet and 2 others
5 facts ▸
  • General meeting, 06/05/2024
  • Director reappointment, Dominic Piscitelli (director)
  • Director reappointment, Serge Goblet (director)
  • Director reappointment, Ami Patel Shah (director)
  • Director reappointment, Christopher LiPuma (director)
28-05
NBB filing Annual accounts filed
fiscal year 2023 · full schema
28-05
NBB filing Annual accounts filed
fiscal year 2023 · consolidated
13-05
State Gazette act Capital & shares · Statutes amendment
Capital decrease · Capital · Power of attorney5 facts ▸
  • General meeting, 06/05/2024
  • Capital decrease, €24.732.646,07
  • Capital, €8.216.154,63
  • Power of attorney, An Phan
  • Statutes amendment
16-04
State Gazette act Permanent representative: Christophe Pelzer
1 fact ▸
  • Permanent representative, Christophe Pelzer (permanent representative)
31-01
State Gazette act Resignation: Syga Bio SARL (délégué à la gestion journalière/ceo)
Appointment: Mel Management srl (délégué à la gestion journalière/ceo ad interim)4 facts ▸
  • Board meeting, 05/12/2023
  • Director resignation, Syga Bio SARL (délégué à la gestion journalière/ceo)
  • Director resignation, Syga Bio SARL (director)
  • Director appointment, Mel Management srl (délégué à la gestion journalière/ceo ad interim)
11-01
State Gazette act Resignations: Hilde Windels (director) and Mel Management SRL (director)
Appointments: Hilde Windels BV (director) and CFIP CLYD LLC (director) · Power of attorney9 facts ▸
  • Board meeting, 13/11/2023
  • Director resignation, Hilde Windels (director)
  • Director resignation, Hilde Windels (chair of the board)
  • Director resignation, Mel Management SRL (director)
  • Director appointment, Hilde Windels BV (director)
  • Director appointment, CFIP CLYD LLC (director)
  • Director appointment, Hilde Windels BV (chair of the board)
  • Power of attorney, An Phan
  • Power of attorney, Adrien Lanotte
2023
31-12
Financial Liquidity doublescurrent ratio 5.76
Current ratio from 2.37 to 5.76; short-term debt falls from €7.58M to €2.41M.
20-12
State Gazette act Appointments: Jonathan James, Sage Mandel and Andrea Gothing
Capital increase · Capital · Statutes amendment14 facts ▸
  • General meeting, 14/11/2023
  • Capital increase, €7.749.999,92
  • Capital, €88.378.224,25
  • Statutes amendment
  • Statutes amendment
  • Statutes amendment
  • Statutes amendment
  • Director appointment, Jonathan James (director)
  • Director appointment, Sage Mandel (director)
  • Director appointment, Andrea Gothing (director)
  • Statutes amendment
  • Statutes amendment
  • +2 further facts in this act
25-09
State Gazette act Registered office
Registered-office move · Power of attorney3 facts ▸
  • Board meeting, 22/06/2023
  • Registered-office move, 9 rue André Dumont à 1435 Mont Saint Guibert
  • Power of attorney, Adrien Lanotte
11-09
State Gazette act Capital & shares
Capital increase · Bank account · Capital9 facts ▸
  • Board meeting, 04/09/2023
  • Capital increase, €2.044.000
  • Bank account, 04/09/2023
  • Capital, €80.628.224,33
  • Share issue, droits de souscription, 598500
  • Statutes amendment, 5
  • Preemptive rights cancellation, émission des droits de souscription, membres du personnel de la Société
  • Conditional capital increase, pair comptable des actions, octroi, acceptation et exercice des droits de souscription
  • Board powers, détermination des bénéficiaires, collecte des acceptations, fixation du prix d'exercice
11-07
State Gazette act Appointments: VCBA BDO Bedrijfsrevisoren - Réviseurs d'entreprises (statutory auditor) and SYGA BIO SARL (director)
3 facts ▸
  • General meeting, 05/05/2023
  • Auditor appointment, VCBA BDO Bedrijfsrevisoren - Réviseurs d'entreprises (statutory auditor)
  • Director appointment, SYGA BIO SARL (director)
05-06
NBB filing Annual accounts filed
fiscal year 2022 · full schema
05-06
NBB filing Annual accounts filed
fiscal year 2022 · consolidated
04-05
State Gazette act Appointment: SYGA BIO SARL (daily management delegate)
Resignations: Mel Management SRL (daily management delegate) and Chris Buyse (director)5 facts ▸
  • Board meeting, 23/03/2023
  • Director appointment, SYGA BIO SARL (daily management delegate)
  • Director resignation, Mel Management SRL (daily management delegate)
  • Director appointment, SYGA BIO SARL (director)
  • Director resignation, Chris Buyse (director)
24-02
State Gazette act Resignation: Chris Buyse (director)
2 facts ▸
  • Board meeting, 13/12/2022
  • Director resignation, Chris Buyse (director)
2022
31-12
Financial Weakest financial yearnet €-39.62M
Net result drops to €-39.62M, the lowest in the series; recovery starts the following year.
14-10
State Gazette act Miscellaneous
Share issue · Capital increase · Waiver of preemptive rights4 facts ▸
  • Board meeting, 05/10/2022
  • Share issue, droits de souscription, 323700
  • Capital increase
  • Waiver of preemptive rights, ja
20-07
State Gazette act Resignations: Filippo Petti (délégué à la gestion journalière et directeur financier) and Michel Lussier (président du conseil d'administration et président du comité de rémunération et de nomination)
Appointments: Mel Management SRL (daily management delegate) and Hilde Windels (chair of the board)7 facts ▸
  • Board meeting, 23/06/2022
  • Director resignation, Filippo Petti (délégué à la gestion journalière et directeur financier)
  • Director appointment, Mel Management SRL (daily management delegate)
  • Director appointment, Hilde Windels (chair of the board)
  • Director appointment, Hilde Windels (présidente du comité de rémunération et de nomination)
  • Director resignation, Michel Lussier (président du conseil d'administration et président du comité de rémunération et de nomination)
  • Director resignation, Filippo Petti (director)
31-05
State Gazette act Reappointment: Hilde Windels (director)
Appointments: Ami Patel SHAH (director) and Christopher LIPUMA (director)4 facts ▸
  • General meeting, 05/05/2022
  • Director reappointment, Hilde Windels (director)
  • Director appointment, Ami Patel SHAH (director)
  • Director appointment, Christopher LIPUMA (director)
24-05
NBB filing Annual accounts filed
fiscal year 2021 · full schema
24-05
NBB filing Annual accounts filed
fiscal year 2021 · consolidated
05-04
State Gazette act Reappointments: Mel Management SRL (director) and Marina Udier Blagovic (director)
Power of attorney4 facts ▸
  • General meeting, 05/05/2021
  • Director reappointment, Mel Management SRL (director)
  • Director reappointment, Marina Udier Blagovic (director)
  • Power of attorney, Adrien Lanotte
24-03
State Gazette act Miscellaneous
Approval · Statutes amendment3 facts ▸
  • Board meeting, 17/03/2022
  • Approval, rapport complémentaire du conseil d'administration
  • Statutes amendment
18-02
State Gazette act Resignation: R.A.D. Life Sciences (director)
Appointment: Christopher LiPuma (director)3 facts ▸
  • Board meeting, 13/01/2022
  • Director resignation, R.A.D. Life Sciences (director)
  • Director appointment, Christopher LiPuma (director)
2021
29-12
State Gazette act Resignation: Maria Koehler (director)
Appointments: Ami Patel SHAH (director) and John Christopher LiPuma (observateur) · Capital increase · Capital6 facts ▸
  • Board meeting, 08/12/2021
  • Capital increase, €22.620.000
  • Capital, €78.584.224,33
  • Director resignation, Maria Koehler (director)
  • Director appointment, Ami Patel SHAH (director)
  • Director appointment, John Christopher LiPuma (observateur)
18-11
State Gazette act Capital & shares
Capital increase · Capital · Statutes amendment4 facts ▸
  • Board meeting, 20/10/2021
  • Capital increase, €1.014.000
  • Capital, €55.964.224,33
  • Statutes amendment
18-11
State Gazette act Miscellaneous
Share issue · Capital increase · Preemption waiver6 facts ▸
  • Board meeting, 11/10/2021
  • Share issue, droits de souscription, 777050
  • Capital increase
  • Preemption waiver, ja
  • Accounting par value, 3.48 EUR
  • Board powers, détermination des bénéficiaires, recueillir l'acceptation, fixer le prix d'exercice
21-10
State Gazette act Resignation: Maria Koehler (director)
2 facts ▸
  • Board meeting, 04/08/2021
  • Director resignation, Maria Koehler (director)
03-09
State Gazette act Capital & shares · Statutes amendment
Capital increase · Capital3 facts ▸
  • Board meeting, 22/07/2021
  • Capital increase, €1.038.000
  • Capital, €54.950.224,33
23-08
State Gazette act Capital & shares
Capital increase · Share issue · Capital6 facts ▸
  • Board meeting, 28/06/2021
  • Capital increase, €1.044.000
  • Share issue, ADS, actions dématérialisées
  • Capital, €53.912.224,33
  • Reserve creation, 294.000,00 EUR, indisponible
  • Preemption waiver, ja
25-06
State Gazette act Capital & shares
Capital increase · Share issue · Bank account4 facts ▸
  • Capital increase, €23.664
  • Share issue, nouvelles actions ... souscrites sous la forme d'ADS
  • Bank account, ING Belgique
  • Capital, €52.868.224,33
09-06
State Gazette act Capital & shares · Statutes amendment · Miscellaneous
Reserve release3 facts ▸
  • General meeting, 25/05/2021
  • Reserve release, Réduction du compte 'Primes d'émission' par apurement des pertes reportées
  • Statutes amendment
25-05
NBB filing Annual accounts filed
fiscal year 2020 · full schema
07-05
State Gazette act Capital & shares · Statutes amendment
Capital increase · Share issue · Capital4 facts ▸
  • Board meeting, 29/04/2021
  • Capital increase, €1.044.000
  • Share issue, ADS, actions dématérialisées
  • Capital, €52.211.200,33
15-04
State Gazette act Capital & shares
Capital increase · Share issue · Bank account5 facts ▸
  • Board meeting, 09/04/2021
  • Capital increase, €1.044.000
  • Share issue, ADS, actions dématérialisées
  • Bank account, 08/04/2021
  • Capital, €51.167.200,33
02-04
State Gazette act Capital & shares
Capital increase · Share issue · Bank account5 facts ▸
  • Board meeting, 29/03/2021
  • Capital increase, €696.000
  • Share issue, ADS, actions dématérialisées
  • Bank account, ING, BE87 3632 0448 1494
  • Capital, €50.123.200,33
20-01
State Gazette act Capital & shares · Statutes amendment
Capital increase · Capital4 facts ▸
  • Board meeting, 08/01/2021
  • Capital increase, €914.585,76
  • Capital, €49.427.200,33
  • Statutes amendment
14-01
State Gazette act Appointment: Marina Udier Blagovic (director)
Resignation: Margo Roberts (director)3 facts ▸
  • Board meeting, 17/12/2020
  • Director appointment, Marina Udier Blagovic (director)
  • Director resignation, Margo Roberts (director)
05-01
State Gazette act Capital & shares
Share issue · Capital increase · Power of attorney4 facts ▸
  • Board meeting, 10/12/2020
  • Share issue, droits de souscription, 561525
  • Capital increase
  • Power of attorney, NandaDevi SRL
2020
30-12
State Gazette act Resignation: Michel Lussier (director)
Appointment: Mel Management SRL (director) · Power of attorney5 facts ▸
  • Board meeting, 04/12/2020
  • Director resignation, Michel Lussier (director)
  • Director appointment, Mel Management SRL (director)
  • Director appointment, Mel Management SRL (chair of the board)
  • Power of attorney, Adrien Lanotte
07-10
State Gazette act Capital & shares
Capital increase · Power of attorney · Statutes amendment5 facts ▸
  • Board meeting, 03/09/2020
  • Capital increase
  • Power of attorney, chaque administrateur de la Société
  • Power of attorney, chaque administrateur
  • Statutes amendment, 5
22-07
State Gazette act Resignations: Debasish Roychowdhury (director) and Rudy Dekeyser (director)
Appointment: Filippo Petti (managing director) · Declaration4 facts ▸
  • Declaration, 25/06/2020
  • Director resignation, Debasish Roychowdhury (director)
  • Director resignation, Rudy Dekeyser (director)
  • Director appointment, Filippo Petti (managing director)
23-06
State Gazette act Appointments: Dominic Piscitelli, R.A.D. Life Sciences BV and CVBA E&Y Bedrijfsrevisoren - Réviseurs d'entreprises
Reappointments: Michel Lussier, Serge Goblet and Chris Buyse · Resignation: VCBA BDO Bedrijfsrevisoren (statutory auditor) · Power of attorney12 facts ▸
  • General meeting, 05/05/2020
  • Director appointment, Dominic Piscitelli (director)
  • Director appointment, R.A.D. Life Sciences BV (director)
  • Director reappointment, Michel Lussier (director)
  • Director reappointment, Serge Goblet (director)
  • Director reappointment, Chris Buyse (director)
  • Auditor appointment, CVBA E&Y Bedrijfsrevisoren - Réviseurs d'entreprises (statutory auditor)
  • Power of attorney, Filippo Petti
  • Power of attorney, NandaDevi SPRL
  • Power of attorney, F&C Consulting Sprl
  • Power of attorney, CMS Belgium
  • Director resignation, VCBA BDO Bedrijfsrevisoren (statutory auditor)
22-06
State Gazette act Resignations & appointments · Miscellaneous
Name change · Statutes amendment3 facts ▸
  • General meeting, 08/06/2020
  • Name change, Celyad Oncology
  • Statutes amendment
15-04
State Gazette act Appointments: Marie Koehler (director) and Filippo Petti (director)
3 facts ▸
  • General meeting, 23/03/2020
  • Director appointment, Marie Koehler (director)
  • Director appointment, Filippo Petti (director)
07-01
State Gazette act Resignation: LSS Consulting (director)
Permanent representative: Christian Homsy · Appointment: Filippo Petti (director)6 facts ▸
  • Board meeting, 28/11/2019
  • Director resignation, LSS Consulting (director)
  • Director resignation, LSS Consulting (président du comité stratégique)
  • Director resignation, LSS Consulting (membre du comité de rémunération et de nomination)
  • Permanent representative, Christian Homsy
  • Director appointment, Filippo Petti (director)
2019
31-10
State Gazette act Miscellaneous
Share issue · Capital increase · Power of attorney5 facts ▸
  • Board meeting, 24/10/2019
  • Share issue, droits de souscription, 939.500
  • Capital increase
  • Power of attorney, NandaDevi SPRL
  • Share cancellation, warrants, 270.700
19-09
State Gazette act Appointments: Michel Lussier, Chris Buyse and 2 others
Power of attorney · Capital increase · Statutes amendment14 facts ▸
  • Board meeting, 11/09/2019
  • Power of attorney, Filippo Petti
  • Power of attorney, Michel Lussier
  • Power of attorney, Chris Buyse
  • Power of attorney, Rudy Dekeyser
  • Capital increase
  • Director appointment, Michel Lussier (membre du comité de détermination du prix)
  • Director appointment, Chris Buyse (membre du comité de détermination du prix)
  • Director appointment, Serge Goblet (membre du comité de détermination du prix)
  • Director appointment, Filippo Petti (membre du comité de détermination du prix)
  • Power of attorney, chaque administrateur
  • Statutes amendment
  • +2 further facts in this act
27-05
State Gazette act Appointment: Dr. Margo Roberts (director)
Power of attorney6 facts ▸
  • General meeting, 06/05/2019
  • Director appointment, Dr. Margo Roberts (director)
  • Power of attorney, Filippo Petti
  • Power of attorney, NandaDevi SPRL
  • Power of attorney, F&C Consulting SPRL
  • Power of attorney, CMS Belgium
16-04
State Gazette act Resignation: LSS Consulting SPRL (daily management delegate)
Appointment: Filippo Petti (daily management delegate)3 facts ▸
  • Board meeting, 28/03/2019
  • Director resignation, LSS Consulting SPRL (daily management delegate)
  • Director appointment, Filippo Petti (daily management delegate)
2018
28-11
State Gazette act Capital & shares
Share issue · Capital increase · Share cancellation5 facts ▸
  • Board meeting, 26/10/2018
  • Share issue, 700.000 Warrants dans le cadre du plan de Warrants 2018, permettant chacun de souscrire à une action nouvelle ordinaire
  • Capital increase
  • Share cancellation, Annulation de 353.050 warrants existants non-alloués
  • Power of attorney, NandaDevi SPRL
09-11
State Gazette act Resignation: Tolefi SA (director)
Appointment: Dr. Margo Roberts (director) · Power of attorney4 facts ▸
  • Board meeting, 22/08/2018
  • Director resignation, Tolefi SA (director)
  • Director appointment, Dr. Margo Roberts (director)
  • Power of attorney, CMS De Backer
15-06
State Gazette act Reappointments: Tolefi SA (director) and Debasish Rowchowdhury (director)
Appointment: Hilde Windels (director) · Permanent representative: Patrick Jeanmart · Approval7 facts ▸
  • General meeting, 07/05/2018
  • Director reappointment, Tolefi SA (director)
  • Director reappointment, Debasish Rowchowdhury (director)
  • Director appointment, Hilde Windels (director)
  • Approval, termes et conditions d'un modèle de plan de warrants
  • Permanent representative, Patrick Jeanmart
  • Power of attorney, Patrick Jeanmart
25-05
State Gazette act Capital & shares
Capital increase · Share issue · Bank account7 facts ▸
  • Capital increase, €7.203.600
  • Share issue, dont 568.500 souscrites sous la forme d'ADS, nouvelles actions
  • Bank account, ING, BE48 3631 7493 8227
  • Capital, €41.552.614,57
  • Statutes amendment
  • Auditor certification, Subscription and full payment of 2,070,000 new shares confirmed
  • Board meeting, 14/05/2018
24-05
State Gazette act Appointments: Chris Buyse, Michel Lussier and 2 others
Power of attorney · Capital increase · Statutes amendment13 facts ▸
  • Board meeting, 14/05/2018
  • Power of attorney, Patrick Jeanmart
  • Power of attorney, Christian Homsy
  • Capital increase
  • Director appointment, Chris Buyse (membre du comité de détermination du prix)
  • Director appointment, Michel Lussier (membre du comité de détermination du prix)
  • Director appointment, Paje (membre du comité de détermination du prix)
  • Director appointment, LSS Consulting (membre du comité de détermination du prix)
  • Power of attorney, chaque administrateur
  • Statutes amendment
  • Subscription deadline, 30/05/2018
  • Minimum issue price, 3.48 EUR
  • +1 further facts in this act
28-02
State Gazette act Capital & shares
Capital increase · Share issue · Bank account5 facts ▸
  • Capital increase, €11.880
  • Share issue, nouvelles actions, 4500
  • Bank account, 29/01/2018
  • Capital, €34.349.014,57
  • Statutes amendment
2017
22-12
State Gazette act Resignation: Chris De Jonghe (director)
Permanent representative: Christian Homsy3 facts ▸
  • Board meeting, 15/09/2017
  • Director resignation, Chris De Jonghe (director)
  • Permanent representative, Christian Homsy
04-12
State Gazette act Capital & shares
Capital increase · Share issue · Bank account4 facts ▸
  • Capital increase, €43.821,76
  • Share issue, nouvelles actions, 5866
  • Bank account, BE35 3631 6811 0437
  • Capital, €34.337.134,57
12-10
State Gazette act Capital & shares
Share issue · Capital increase3 facts ▸
  • Board meeting, 27/09/2017
  • Share issue, Warrants, 520000
  • Capital increase
07-09
State Gazette act Capital & shares
Capital increase · Share issue · Capital5 facts ▸
  • Board meeting, 23/08/2017
  • Capital increase, €1.141.412,18
  • Share issue, nominatives, 328275
  • Capital, €34.293.312,81
  • Statutes amendment
25-08
State Gazette act Capital & shares
Capital increase · Share issue · Bank account6 facts ▸
  • Capital increase, €20.988
  • Share issue, nouvelles actions, 7950
  • Bank account, 28/07/2017
  • Capital, €33.151.900,63
  • Statutes amendment
  • Warrant exercise, 7950, nouvelle action ordinaire
02-08
State Gazette act Capital & shares · Statutes amendment
Share issue7 facts ▸
  • General meeting, 29/06/2017
  • Statutes amendment, 7.1
  • Statutes amendment, 7.3
  • Share issue, Approbation du Plan de warrants 2017: émission et octroi d'un maximum de 520.000 warrants
  • Statutes amendment, 2
  • Statutes amendment, 22
  • Statutes amendment, 7.4
30-06
State Gazette act Appointment: CVBA BDO Bedrijfsrevisoren - Réviseurs d'entreprises (statutory auditor)
2 facts ▸
  • General meeting, 05/05/2017
  • Auditor appointment, CVBA BDO Bedrijfsrevisoren - Réviseurs d'entreprises (statutory auditor)
22-05
State Gazette act Capital & shares
Capital increase · Share issue · Bank account5 facts ▸
  • Capital increase, €12.936
  • Share issue, nouvelles actions, 4900
  • Bank account, BE03 3630 6653 6784
  • Capital, €33.130.912,63
  • Statutes amendment
21-02
State Gazette act Capital & shares · Statutes amendment
Capital increase · Share issue · Bank account6 facts ▸
  • Board meeting, 27/01/2017
  • Capital increase, €547.140
  • Share issue, nouvelles actions, 207250
  • Bank account, ING Belgique, 363-0628275-46
  • Capital, €33.117.976,63
  • Statutes amendment
10-01
State Gazette act Resignation: Danny Wong (director)
Power of attorney3 facts ▸
  • Board meeting, 16/09/2016
  • Director resignation, Danny Wong (director)
  • Power of attorney, Lionel Duez
2016
28-12
State Gazette act Capital & shares
Share issue · Capital increase3 facts ▸
  • Board meeting, 12/12/2016
  • Share issue, émission de 100.000 Warrants dans le cadre du plan de Warrants 2016, permettant chacun de souscrire à une action nouvelle ordinaire
  • Capital increase
19-10
State Gazette act Reappointment: LSS Consulting SPRL (administrateur exécutif)
Permanent representative: Christian Homsy3 facts ▸
  • General meeting, 09/05/2016
  • Director reappointment, LSS Consulting SPRL (administrateur exécutif)
  • Permanent representative, Christian Homsy
09-06
State Gazette act Reappointments: Chris Buyse, Rudy Dekeyser and 2 others
Resignation: William Wijns (director) · Registered-office move8 facts ▸
  • Board meeting, 18/03/2016
  • Registered-office move, Rue Edouard Belin 2, 1435 Mont-Saint-Guibert, Belgique
  • General meeting, 09/05/2016
  • Director reappointment, Chris Buyse (independent director)
  • Director reappointment, Rudy Dekeyser (independent director)
  • Director reappointment, Michel Lussier (administrateur non exécutif)
  • Director reappointment, Serge Goblet (administrateur non exécutif)
  • Director resignation, William Wijns (director)
2015
21-12
State Gazette act Resignations: Pienter-Jan BVBA (director) and R.A.D. Life Sciences BVBA (director)
Appointments: Chris Buyse, Rudy Dekeyser and LSS Consulting SPRL · Permanent representative: Christian Homsy · Power of attorney10 facts ▸
  • Board meeting, 22/09/2015
  • General meeting, 05/11/2015
  • Director resignation, Pienter-Jan BVBA (director)
  • Director resignation, R.A.D. Life Sciences BVBA (director)
  • Director appointment, Chris Buyse (independent director)
  • Director appointment, Rudy Dekeyser (independent director)
  • Permanent representative, Christian Homsy
  • Director appointment, LSS Consulting SPRL (managing director)
  • Director appointment, LSS Consulting SPRL (daily management delegate)
  • Power of attorney, Lionel Duez
02-12
State Gazette act Miscellaneous
Share issue1 fact ▸
  • Share issue, warrants pour le personnel, certains prestataires de services et administrateurs
09-11
State Gazette act Resignation: Jean-Marc Heynderickx (director)
Appointment: Debasish Roychowdhury (independent director) · Permanent representative: Christian Homsy4 facts ▸
  • Board meeting, 21/08/2015
  • Director resignation, Jean-Marc Heynderickx (director)
  • Director appointment, Debasish Roychowdhury (independent director)
  • Permanent representative, Christian Homsy
04-09
State Gazette act Capital & shares
Share issue · Capital increase · Capital4 facts ▸
  • Share issue, actions nouvelles ordinaires, sans désignation de valeur nominale, 5916
  • Capital increase, €20.706
  • Capital, €32.570.836,63
  • Statutes amendment
15-07
State Gazette act Capital & shares
Capital increase · Capital · Statutes amendment4 facts ▸
  • Capital increase, €87.965.000
  • Capital, €32.550.130,63
  • Statutes amendment, 5
  • Statutes amendment, 7
02-06
State Gazette act Capital & shares
Share issue · Bank account · Capital increase5 facts ▸
  • Share issue, actions nouvelles ordinaires, 500
  • Bank account, ING Banque, BE78 3631 4695 9686
  • Capital increase, €1.750
  • Capital, €27.440.130,63
  • Statutes amendment
28-05
State Gazette act Resignations & appointments
Name change · Power of attorney3 facts ▸
  • General meeting, 05/05/2015
  • Name change, Celyad
  • Power of attorney, Cardio³ BioSciences
25-03
State Gazette act Capital & shares
Capital increase · Capital · Statutes amendment4 facts ▸
  • Capital increase, €2.496.830
  • Capital, €27.438.380,63
  • Statutes amendment, 5
  • Statutes amendment, 7
25-03
State Gazette act Appointments: Tolefi SA (administrateur non exécutif) and Danny Wong (administrateur non exécutif)
3 facts ▸
  • General meeting, 26/11/2014
  • Director appointment, Tolefi SA (administrateur non exécutif)
  • Director appointment, Danny Wong (administrateur non exécutif)
26-02
State Gazette act Capital & shares
Share issue · Capital increase · Capital5 facts ▸
  • Board meeting, 07/02/2015
  • Share issue, actions nouvelles ordinaires, sans désignation de valeur nominale, 333
  • Capital increase, €1.165,5
  • Capital, €24.941.550,63
  • Statutes amendment
13-02
State Gazette act Capital & shares
Capital increase · Share issue · Capital7 facts ▸
  • Board meeting, 21/01/2015
  • Capital increase, €325.804,5
  • Share issue, actions nouvelles ordinaires, 93087
  • Capital, €24.940.385,13
  • Statutes amendment
  • Power of attorney, LSS Consulting SPRL
  • Power of attorney, Patrick Jeanmart SPRL
2014
28-11
State Gazette act Capital & shares
Capital increase · Share issue · Bank account5 facts ▸
  • Capital increase, €17.500
  • Share issue, actions nouvelles ordinaires, sans désignation de valeur nominale, 5.000
  • Bank account, ING Banque, BE 91 3631 4015 8976
  • Capital, €24.614.580,63
  • Statutes amendment
25-08
State Gazette act Capital & shares
Share issue · Capital increase · Capital4 facts ▸
  • Share issue, actions nouvelles ordinaires, 5750
  • Capital increase, €20.125
  • Capital, €24.597.080,63
  • Statutes amendment
22-08
State Gazette act Resignation: Sparaxis SA (director)
Permanent representative: Christian Homsy2 facts ▸
  • Director resignation, Sparaxis SA (director)
  • Permanent representative, Christian Homsy
29-07
State Gazette act Appointment: PwC Réviseurs d'Entreprises SCCRL (statutory auditor)
Permanent representatives: Patrick Mortroux and Christian Homsy4 facts ▸
  • General meeting, 05/05/2014
  • Auditor appointment, PwC Réviseurs d'Entreprises SCCRL
  • Permanent representative, Patrick Mortroux
  • Permanent representative, Christian Homsy
29-07
State Gazette act Resignation: Christian Homsy (director)
Appointments: LSS Consulting SPRL, Hanspeter Spek and R.A.D.Life Sciences BVBA · Permanent representative: Rudy Dekeyser6 facts ▸
  • General meeting, 05/05/2014
  • Director resignation, Christian Homsy (director)
  • Director appointment, LSS Consulting SPRL (administrateur exécutif)
  • Director appointment, Hanspeter Spek (independent director)
  • Director appointment, R.A.D.Life Sciences BVBA (membre du conseil)
  • Permanent representative, Rudy Dekeyser
22-07
State Gazette act Permanent representative: HOMSY Christian Cherif
Appointment: LSS Consulting SPRL (director) · Capital increase · Capital6 facts ▸
  • Board meeting, 16 juin 2014
  • Permanent representative, HOMSY Christian Cherif
  • Capital increase
  • Capital, €24.576.955,63
  • Statutes amendment, 7
  • Director appointment, LSS Consulting SPRL
09-07
State Gazette act Capital & shares · Statutes amendment
Capital increase · Capital4 facts ▸
  • Board meeting, 16/06/2004
  • Capital increase, €12.499.960
  • Capital, €23.582.640,63
  • Statutes amendment
05-06
State Gazette act Capital & shares
Capital increase · Capital · Statutes amendment3 facts ▸
  • Capital increase, €8.271,2
  • Capital, €22.588.325,63
  • Statutes amendment
31-03
State Gazette act Resignation: Rudy Dekeyser (director)
Appointment: R.A.D. Life Sciences BVBA (director) · Permanent representative: Rudy Dekeyser4 facts ▸
  • Board meeting, 13/12/2013
  • Director resignation, Rudy Dekeyser (director)
  • Director appointment, R.A.D. Life Sciences BVBA (director)
  • Permanent representative, Rudy Dekeyser
19-03
State Gazette act Permanent representative: Golenvaux Eric
1 fact ▸
  • Permanent representative, Golenvaux Eric
21-02
State Gazette act Capital & shares
Capital increase · Share issue · Capital4 facts ▸
  • Capital increase, €442.046,5
  • Share issue, actions nouvelles ordinaires, sans désignation de valeur nominale entièrement libérées, 126299
  • Capital, €22.580.054,43
  • Statutes amendment
2013
31-10
State Gazette act Resignation: Jan Andersson (director)
1 fact ▸
  • Director resignation, Jan Andersson (director)
14-10
State Gazette act Appointments: Chris De Jonghe (director) and SPARAXIS (director)
Permanent representative: Jean Séquaris · Statutes amendment · Mandate compensation8 facts ▸
  • General meeting, 26/09/2013
  • Statutes amendment
  • Statutes amendment
  • Director appointment, Chris De Jonghe (director)
  • Director appointment, SPARAXIS (director)
  • Permanent representative, Jean Séquaris
  • Mandate compensation, Chris De Jonghe
  • Mandate compensation, SPARAXIS
16-08
State Gazette act Capital & shares · Statutes amendment
Capital increase · Share issue · Capital4 facts ▸
  • Capital increase, €725.287,5
  • Share issue, actions nouvelles ordinaires sans désignation de valeur nominale, 207.225
  • Capital, €22.138.007,93
  • Statutes amendment
26-07
State Gazette act Capital & shares
Capital increase · Capital · Share issue10 facts ▸
  • General meeting, 11/06/2013
  • Capital increase, €4.835.250
  • Capital, €21.412.720,43
  • Share issue, Over-allotment Warrant
  • Power of attorney, Patrick Jeanmart
  • Statutes amendment
  • Warrant cancellation, warrants anti-dilutifs
  • Share conversion, Suppression des catégories existantes d'actions et conversion en actions ordinaires
  • Authorised capital, 21.412.720,43 EUR
  • Legal-form change, société anonyme faisant ou ayant fait publiquement appel à l'épargne
24-06
State Gazette act Capital & shares · Statutes amendment
Share issue · Capital increase · Capital4 facts ▸
  • Share issue, warrants, 253150
  • Capital increase, €24.091,76
  • Capital, €16.577.470,43
  • Statutes amendment
20-06
State Gazette act Capital & shares
Capital increase · Share issue · Capital9 facts ▸
  • Board meeting, 31/05/2013
  • Capital increase, €1.552.729,26
  • Share issue, warrants investisseurs
  • Share issue, warrants en faveur de certains membres du personnel, du management et des administrateurs
  • Capital, €16.553.378,67
  • Statutes amendment
  • Suspensive condition, non réalisée, 20/01/2011
  • Potential capital increase, exercice des warrants du personnel, du management et des administrateurs, 542.400,00 EUR
  • General meeting, 06/05/2013
05-06
State Gazette act Capital & shares · Statutes amendment
Capital increase · Capital · Share issue11 facts ▸
  • General meeting, 06/05/2013
  • Capital increase, €5.026.142
  • Capital, €15.000.649,41
  • Share issue, classe B, 221.238
  • Share issue, droits de souscription (Warrants Incitatifs), 266.241
  • Statutes amendment
  • Power of attorney, Christian HOMSY
  • Power of attorney, Patrick JEANMART
  • Power of attorney, CARDIO BioSciences
  • Power of attorney, CARDIO BioSciences
  • Power of attorney, CARDIO BioSciences
21-03
State Gazette act Resignation: Louise Proulx (director)
Appointment: Jean-Marc Heynderickx (director) · Share issue · Capital increase11 facts ▸
  • General meeting, 31 janvier 2013
  • Share issue, 140.000, personnel, management et administrateurs
  • Capital increase, €632.800
  • Share issue, 140, Warrants Anti-Dilutifs
  • Director resignation, Louise Proulx (director)
  • Director discharge, Louise Proulx
  • Director appointment, Jean-Marc Heynderickx (director)
  • Power of attorney, Cardio 3 BioSciences
  • Power of attorney, Cardio 3 BioSciences
  • Power of attorney, Cardio 3 BioSciences
  • Power of attorney, Cardio 3 BioSciences
2012
17-04
State Gazette act Capital & shares
Share issue · Power of attorney · Capital increase8 facts ▸
  • General meeting, 21/03/2012
  • Share issue, Warrants anti-dilutifs, 70
  • Power of attorney, directors
  • Power of attorney, director
  • Capital increase, €égal au prix de l'exercice des Warrants Anti-dilutifs
  • Waiver of preemptive rights, émission des Warrants Anti-dilutifs
  • Report approval, émission de warrants, commissaire
  • Loan, Loan E
04-04
State Gazette act Appointment: Ernst & Young (commissaire réviseur)
Permanent representative: Wuyts Daniel3 facts ▸
  • General meeting, 05/05/2011
  • Auditor appointment, Ernst & Young (commissaire réviseur)
  • Permanent representative, Wuyts Daniel
2011
06-06
State Gazette act Capital & shares
Capital decrease · Capital · Power of attorney4 facts ▸
  • General meeting, 05/05/2011
  • Capital decrease, €18.925.474,35
  • Capital, €9.974.507,41
  • Power of attorney, conseil d'administration ou deux administrateurs
22-02
State Gazette act Resignations: Michel Lussier, Christian Homsy and 5 others
Appointments: Michel Lussier, Christian Homsy and 6 others · Permanent representative: Chris Buyse · Statutes amendment19 facts ▸
  • General meeting, 20 janvier 2011
  • Statutes amendment
  • Director resignation, Michel Lussier (director)
  • Director resignation, Christian Homsy (director)
  • Director resignation, Serge Goblet (director)
  • Director resignation, Chris Buyse (director)
  • Director resignation, Rudy Dekeyser (director)
  • Director resignation, William Wijns (director)
  • Director resignation, Peter Wilhelm (director)
  • Director appointment, Michel Lussier (director)
  • Director appointment, Christian Homsy (director)
  • Director appointment, Serge Goblet (director)
  • +7 further facts in this act
31-01
State Gazette act Capital & shares · Resignations & appointments
Share issue · Capital4 facts ▸
  • Share issue, 50.000 warrants accepted and subscribed, max 50.000 Class B shares to be created, max capital increase 1.122.000,00 EUR
  • Share issue, 5.000 warrants B accepted and subscribed, max 5.000 Class B shares to be created, max capital increase 176.800,00 EUR
  • Share issue, 61.050 warrants accepted and subscribed, max 61.050 Class A shares to be created, max capital increase 2.158.728,00 EUR
  • Capital, €28.899.981,76
2010
01-12
State Gazette act Capital & shares
Capital increase · Capital · Share issue12 facts ▸
  • General meeting, 29 octobre 2010
  • Capital increase, €471.240
  • Capital increase, €3.069.911
  • Capital increase, €5.274.403,68
  • Capital increase, €2.609.320,48
  • Capital increase, €399.921,6
  • Capital increase, €276.012
  • Capital, €28.899.983,28
  • Share issue, 79.500, Warrants
  • Power of attorney, Comité de Rémunération
  • Power of attorney, Christian Homsy
  • Power of attorney, CARDIO BioSciences
30-11
State Gazette act Capital & shares
Share issue2 facts ▸
  • Share issue, Warrants A accepted and subscribed
  • Share issue, Warrants C accepted and subscribed
03-06
State Gazette act Appointments: Christian Homsy, Michel Lussier and William Wijns
Approval · Director discharge · Share issue10 facts ▸
  • General meeting, 05/05/2010
  • Approval, Approbation des comptes de l'exercice 2009, clôturés le 31 décembre 2009
  • Director discharge, CARDIO3 BioSciences
  • Share issue, warrants, 50000
  • Director appointment, Christian Homsy (director)
  • Director appointment, Michel Lussier (director)
  • Director appointment, William Wijns (director)
  • Officer mandate change
  • Financial result, 4.545.046,91 EUR, carried forward to next exercise
  • Warrant allocation
2008
13-10
State Gazette act Registered office · Capital & shares · Statutes amendment
Share issue · Registered-office move4 facts ▸
  • General meeting, 26/09/2008
  • Share issue, Emission d'un plan de nonante mille (90.000) warrants
  • Registered-office move, 1435 Mont Saint Guibert, Rue Edouard Belin n°12
  • Statutes amendment
2007
06-08
State Gazette act Incorporation
Appointments: Michel LUSSIER, Christian HOMSY and 2 others · Founding capital · Mandate compensation13 facts ▸
  • Incorporation, 24/07/2007
  • Founding capital, €62.500
  • Director appointment, Michel LUSSIER (director)
  • Director appointment, Christian HOMSY (director)
  • Director appointment, William WIJNS (director)
  • Director appointment, Michel LUSSIER (président du conseil)
  • Director appointment, Christian HOMSY (managing director)
  • Mandate compensation, Christian HOMSY
  • Mandate compensation, Michel LUSSIER
  • Auditor appointment, Ernst & Young Réviseurs d'Entreprises
  • Power of attorney, Virginie Maselis
  • Power of attorney, Bertrand Grimmonpré
  • +1 further facts in this act
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
113 of 115 acts read
About the unread acts

Of the 115 Belgian State Gazette acts we know for this company, 113 have been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
20 directors, last change in 2025
Resilient ID
Délégué à la gestion journalière / directeur général · since 12-11-2025 · Private limited company
Current
Sharon Roberg-Perez
Director · since 16-09-2025
Current
Hilde Windels BV
Director · since 11-01-2024 · Legal entity
Current
CFIP CLYD LLC
Director · since 14-11-2023 · Legal entity
Current
Jonathan James
Director · since 14-11-2023
Current
Sage Mandel
Director · since 14-11-2023
Current
14 other directors
Christopher LiPuma
Director · since 20-01-2022
Current
John Christopher LiPuma
Observateur · since 08-12-2021
Current
Marina Udier Blagovic
Director · since 17-12-2020
Current
Dominic Piscitelli
Director · since 05-05-2020
Current
Serge Goblet
Director · since 20-01-2011
Current
R.A.D. Life Sciences BV
Director · since 05-05-2020 · Legal entity
Not recently confirmed
Marie Koehler
Director · since 23-03-2020
Not recently confirmed
Debasish Rowchowdhury
Director
Not recently confirmed
Paje
Membre du comité de détermination du prix · since 14-05-2018 · Legal entity
Not recently confirmed
TOLEFI
Administrateur non exécutif · since 25-03-2015 · Public limited company
Not recently confirmed
Hanspeter Spek
Independent director · since 05-05-2014
Not recently confirmed
Life Science Strategy Consulting
Administrateur exécutif · since 05-05-2014 · Private limited company · perm. rep.: HOMSY Christian Cherif
Not recently confirmed
R.A.D. LIFE SCIENCES
Membre du conseil · since 13-12-2013 · Private limited company · perm. rep.: Rudy Dekeyser
Not recently confirmed
Jan Anderson
Independent director · since 20-01-2011
Not recently confirmed
05-12-2025 Ami Patel Shah: Resigned as Director
01-12-2025 KANE Matthew Roy: Resigned as Délégué à la gestion journalière/ceo
12-11-2025 Resilient ID: Appointed as Délégué à la gestion journalière / directeur général
16-09-2025 Sharon Roberg-Perez: Appointed as Director
16-09-2025 Andrea Gothing: Resigned as Director
Full history in the Timeline (126 changes) →
Not every act has been read: a resignation may be missing here
2 of this company's 115 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Mont-Saint-Guibert · 1 establishment unit since 2015
Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Rue Emile Francqui 61435 Mont-Saint-Guibert
1 establishment unit
Celyad
Rue Emile Francqui 6, 1435 Mont-Saint-GuibertManufacture of basic pharmaceutical products and pharmaceutical preparations
since 20152.247.587.394

Statutory auditor

1 auditor
VCBA BDO Bedrijfsrevisoren - Réviseurs d'entreprisesCurrent
Statutory auditor
11-07-2023 → present
Show 3 earlier auditors
CVBA BDO Bedrijfsrevisoren - Réviseurs d'entreprises
Statutory auditor
succeeded by VCBA BDO Bedrijfsrevisoren - Réviseurs d'entreprises in 2023
30-06-2017 → 11-07-2023
CVBA E&Y Bedrijfsrevisoren - Réviseurs d'entreprises
Statutory auditor
succeeded by SCCRL PwC Réviseurs d'Entreprises in 2014
06-08-2007 → 29-07-2014
SCCRL PwC Réviseurs d'Entreprises
Auditor · represented by Patrick Mortroux
succeeded by CVBA BDO Bedrijfsrevisoren - Réviseurs d'entreprises in 2017
29-07-2014 → 30-06-2017

Articles of association

Purpose
Le développement de nouvelles technologies médicales et notamment mais non exclusivement la recherche et le développement, la fabrication et la commercialisation d'éléments et de…
Full purpose

Le développement de nouvelles technologies médicales et notamment mais non exclusivement la recherche et le développement, la fabrication et la commercialisation d'éléments et de systèmes en ce compris les procédures, les formules, les méthodes de développement et de fabrication, les instruments et le matériel, les matériaux et les produits, les prototypes, les logiciels et programmes techniques et de recherche, le design, les brevets et les marques, tous liés directement ou indirectement aux biotechnologies et notamment mais non exclusivement les thérapies cellulaires et les différentes matières scientifiques, opérationnelles, légales et financières qui y sont liées directement ou indirectement.

according to the deed of 26-07-2013

Structure & network

Connections & network

23 connected companies
Depth
Aelin Therapeutics, Shared director ATAelinTherapeuticsBELGENEXT, Shared director BBELGENEXTBioSenic, Shared director BBioSenicBIOTECH FONDS VLAANDEREN, Shared director BFBIOTECH FONDSVLAANDERENCatalent Gosselies, Shared director CGCatalentGosseliesCATALENT GOSSELIES HOLDING, Shared director CGCATALENTGOSSELIES…Fluvius System Operator, Shared director FSFluvius SystemOperatorFondation Francqui, Shared director FFFondationFrancquiFund+, Shared director FFund+Gimv, Shared director GGimvGybe Therapeutics, Shared director GTGybeTherapeuticsiTeos Belgium, Shared director IBiTeos BelgiumMEDPOLE, Shared director MMEDPOLENEXTGEN, Shared director NNEXTGENCelyad Oncology CelyadOncology0891.118.115
Shared directors
This company Company Director Shareholding Click a node to look further, drag to arrange, scroll to zoom.
Linked via shared directors
Aelin Therapeutics
Shared director
→
BELGENEXT
Shared director
→
BioSenic
Shared director
→
→
Show 19 more companies with a shared director
Catalent Gosselies
Shared director
→
→
→
Fondation Francqui
Shared director
→
Fund+
Shared director
→
Gimv
Shared director
→
Gybe Therapeutics
Shared director
→
iTeos Belgium
Shared director
→
MEDPOLE
Shared director
→
NEXTGEN
Shared director
→
→
OCTOGOLD
Shared director
→
PIENTER-JAN
Shared director
→
SOFIA
Shared director
→
ViroVet
Shared director
→
VLAAMS INNOVATIEFONDS
Shared director
→
VLAAMSE ENERGIEHOLDING
Shared director
→

Capital and shareholders

Shareholders according to the acts
After the capital increase act of 22-07-2014 ↗
  • Medisun International Limited 284,090 shares
After 6 capital increases act of 01-12-2010 ↗
  • TOLEFI
  • S.R.I.W. Techno
  • Hunza Venures II SCA
  • Mayo Foundation for Medical Education and Research
  • Umbrela Investments Inc.
  • Life Sciences Research Partners VZW
  • GRIFOLS S.A.
  • Jacques Hayez
  • Michel Lussier
  • Christian Homsy
  • Patrick Jeanmart
  • Isabella Gabrielli
  • Didier Mulders
  • Cardiovasculair Onderzoek Aalst CVBA
  • Jacques Demortier
  • Frederic Van Swieten
  • Brigitte Cauwe 900 shares
  • Cap Hatteras
At incorporation act of 06-08-2007 ↗

The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years
  1. 31-07-2026 Capital increase of 500,000 EUR · to 9,716,154.53 EUR
  2. 21-08-2025 Capital increase of 999,999.90 EUR · to 9,216,154.53 EUR
  3. 13-05-2024 Capital reduction of 24,732,646.07 EUR · to 8,216,154.63 EUR · to absorb losses
  4. 20-12-2023 Capital increase of 7,749,999.92 EUR · to 88,378,224.25 EUR
  5. 11-09-2023 Capital increase of 2,044,000 EUR · to 80,628,224.33 EUR · 3,930,770 new shares
  6. 29-12-2021 Capital increase of 22,620,000 EUR · to 78,584,224.33 EUR
  7. 18-11-2021 Capital increase of 1,014,000 EUR · to 55,964,224.33 EUR · 300,000 new shares
  8. 03-09-2021 Capital increase of 1,038,000 EUR · to 54,950,224.33 EUR · 300,000 new shares
Show 40 older capital entries
  1. 23-08-2021 Capital increase of 1,044,000 EUR · to 53,912,224.33 EUR · 300,000 new shares
  2. 25-06-2021 Capital increase of 23,664 EUR · to 52,868,224.33 EUR · 6,800 new shares
  3. 07-05-2021 Capital increase of 1,044,000 EUR · to 52,211,200.33 EUR · 300,000 new shares
  4. 15-04-2021 Capital increase of 1,044,000 EUR · to 51,167,200.33 EUR · 300,000 new shares
  5. 02-04-2021 Capital increase of 696,000 EUR · to 50,123,200.33 EUR · 200,000 new shares
  6. 20-01-2021 Capital increase of 914,585.76 EUR · to 49,427,200.33 EUR · 262,812 new shares
  7. 25-05-2018 Capital increase of 7,203,600 EUR · to 41,552,614.57 EUR
  8. 28-02-2018 Capital increase of 11,880 EUR · to 34,349,014.57 EUR · 4,500 new shares
  9. 04-12-2017 Capital increase of 43,821.76 EUR · to 34,337,134.57 EUR · 5,866 new shares
  10. 07-09-2017 Capital increase of 1,141,412.18 EUR · to 34,293,312.81 EUR · 328,275 new shares
  11. 25-08-2017 Capital increase of 20,988 EUR · to 33,151,900.63 EUR · 7,950 new shares
  12. 22-05-2017 Capital increase of 12,936 EUR · to 33,130,912.63 EUR · 4,900 new shares · in cash
  13. 21-02-2017 Capital increase of 547,140 EUR · to 33,117,976.63 EUR · 207,250 new shares · “exercice de droits de souscription (Warrants)”
  14. 04-09-2015 Capital increase of 20,706 EUR · to 32,570,836.63 EUR
  15. 15-07-2015 Capital increase of 87,965,000 EUR · to 32,550,130.63 EUR
  16. 02-06-2015 Capital increase of 1,750 EUR · to 27,440,130.63 EUR
  17. 25-03-2015 Capital increase of 2,496,830 EUR · to 27,438,380.63 EUR
  18. 26-02-2015 Capital increase of 1,165.50 EUR · to 24,941,550.63 EUR
  19. 13-02-2015 Capital increase of 325,804.50 EUR · to 24,940,385.13 EUR · 93,087 new shares
  20. 28-11-2014 Capital increase of 17,500 EUR · to 24,614,580.63 EUR · 5 new shares
  21. 25-08-2014 Capital increase of 20,125 EUR · to 24,597,080.63 EUR
  22. 22-07-2014 Capital stated in the act · 24,576,955.63 EUR · 7,029,637 shares
  23. 09-07-2014 Capital increase of 12,499,960 EUR · 284,090 new shares
  24. 05-06-2014 Capital increase of 8,271.20 EUR · to 22,588,325.63 EUR
  25. 21-02-2014 Capital increase of 442,046.50 EUR · to 22,580,054.43 EUR · 126,299 new shares
  26. 16-08-2013 Capital increase of 725,287.50 EUR · to 22,138,007.93 EUR
  27. 26-07-2013 Capital increase of 4,835,250 EUR · to 21,412,720.43 EUR
  28. 24-06-2013 Capital increase of 24,091.76 EUR · to 16,577,470.43 EUR · 2,409,176 new shares
  29. 20-06-2013 Capital increase of 1,552,729.26 EUR · to 16,553,378.67 EUR
  30. 05-06-2013 Capital increase of 5,026,142 EUR · to 15,000,649.41 EUR · in kind
  31. 21-03-2013 Capital increase of 632,800 EUR
  32. 06-06-2011 Capital reduction of 18,925,474.35 EUR · to 9,974,507.41 EUR · to absorb losses
  33. 31-01-2011 Capital stated in the act · 28,899,981.76 EUR
  34. 01-12-2010 Capital increase of 471,240 EUR · to 17,270,414.52 EUR · 21 new shares
  35. 01-12-2010 Capital increase of 3,069,911 EUR · to 20,340,325.52 EUR · in kind
  36. 01-12-2010 Capital increase of 5,274,403.68 EUR · to 25,614,729.20 EUR · in kind
  37. 01-12-2010 Capital increase of 2,609,320.48 EUR · to 28,224,049.68 EUR
  38. 01-12-2010 Capital increase of 399,921.60 EUR · to 28,623,971.28 EUR
  39. 01-12-2010 Capital increase of 276,012 EUR · to 28,899,983.28 EUR
  40. 06-08-2007 Incorporation · 62,500 EUR · 409,375 shares

Recognitions · licences · registrations

Legal Entity Identifier

549300ORR0M8XF56OI64
live in the LEI register

Similar companies · same sector, comparable size

Axis44
BE 0767.829.828
Jodoigne · Eq €2.24M
Dokter Geert De Bruecker - Neuropsychiatrie
BE 0471.670.022
Lede · Eq €2.26M
POULPHARM
BE 0888.282.250
Izegem · Eq €2.17M
CENTRE D'ETUDE ET DE TRAITEMENT EN OPHTALMOLOGIE
BE 0826.214.623
Brussel · Eq €2.32M
Inhatarget Therapeutics
BE 0732.994.752
Charleroi · Eq €2.16M
Of 762 companies in sector 72101 we hold annual accounts for 481. 253 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPublic limited company
Founded24-07-2007
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
96999Other personal services
Contact
Website www.celyad.com

Scores and ratios are computed by Checked and are not a credit decision.

General meetings

11 convocations
Extraordinary general meeting
on 06-05-2024 at 15u · published 05-04-2024
Agenda
DE L’ASSEMBLEE GENERALE ORDINAIRE : 1. Prise de connaissance du rapport spécial établi par le conseil d’administration conformément à l’article 7 :228 du Code des sociétés et des associations et des mesures proposées par le conseil d’adminis- tration Commentaires sur ce point de l’ordre du jour : le conseil d’adminis- tration prie l’assemblée générale des actionnaires de prendre connais- sance du rapport susmentionné. 2. Décision relative à la poursuite des activités de la Société et approbation des mesures correctives éventuelles proposées par le conseil d’administration Proposition de résolution : l’assemblée générale des actionnaires décide, notamment au vu du rapport susmentionné, (i) de ...
Extraordinary general meeting
on 25-10-2023 at 14u · published 22-09-2023
Agenda
figure ci-dessous. ORDRE DU JOUR : 1. Prise de connaissance du rapport spécial du conseil d’administra- tion relatif à l’émission de nouvelles actions ordinaires, avec suppres- sion du droit de préférence des actionnaires existants, établi conformé- ment aux articles 7 :179, 7 :191 et 7 :193 du Code des sociétés et des associations. 2. Prise de connaissance du rapport spécial du commissaire, conformément aux articles 7 :179, 7 :191 et 7 :193 du Code des sociétés et des associations, évaluant si les données financières et comptables contenues dans le rapport du conseil d’administration sont exactes et suffisantes dans tous leurs aspects significatifs
Extraordinary general meeting
on 25-05-2021 at 14u · published 02-04-2021
Agenda
DE L’ASSEMBLEE GENERALE ORDINAIRE 1. Délibération sur le rapport annuel du conseil d’administration ayant trait à l’exercice social clôturé le 31 décembre 2020 et sur le rapport du commissaire ayant trait à l’exercice social clôturé le 31 décembre 2020 Commentaires sur ce point de l’ordre du jour : Le conseil d’administra- tion prie l’assemblée générale des actionnaires de prendre note du rapport annuel du conseil d’administration ayant trait à l’exercice social clôturé le 31 décembre 2020 et du rapport du commissaire ayant trait à l’exercice social clôturé le 31 décembre 2020. 2. Délibération sur le rapport de rémunération de la Société, comme exposé par le comité de nomination et de rémuné ...
Extraordinary general meeting
on 23-03-2020 at 15u · published 19-02-2020
Agenda
figure ci-dessous. Dans la mesure où le quorum de présence ne serait pas atteint lors de l’assemblée générale du 23 mars 2020, le conseil d’administration convoque, également par la présente, les actionnaires et détenteurs de warrants à une seconde assemblée générale le 5 mai 2020, à 9 heures (CET), au siège social de la Société, ayant le même ordre du jour. ORDRE DU JOUR : 1. Prise de connaissance du rapport spécial du conseil d’administra- tion établi en application de l’article 7 :199 du Code des sociétés et des associations. 2. Renouvellement du capital autorisé. Proposition de résolution : l’assemblée générale décide d’approuver le renouvellement de l’autorisation de recourir à la techn ...
Extraordinary general meeting
on 23-05-2019 at 10u · published 06-05-2019
figure ci-dessous. Dans la mesure où une première réunion de l’assemblée a été convoquée
Show 6 more convocations
Extraordinary general meeting
on 29-06-2017 at 10u · published 12-06-2017
de l’assemblée demeure identique à celui figurant dans la convocation
Extraordinary general meeting
on 12-06-2017 at 14u · published 11-05-2017
Agenda
figure ci-dessous. Dans la mesure où le quorum de présence ne serait pas atteint lors de l’assemblée générale du 12 juin 2017, le conseil d’administration convoque, également par la présente, les actionnaires et détenteurs de warrants à une seconde assemblée générale le 29 juin 2017, à 10 heures (CET), au siège social de la Société, ayant le même ordre du jour. Ordre du jour de l’assemblée générale extraordinaire : 1. Prise de connaissance du rapport spécial du conseil d’administra- tion rédigé conformément à l’article 604 du Code des sociétés. 2. Pouvoirs conférés au conseil d’administration en vue d’augmenter le capital dans le cadre du capital autorisé. Proposition de résolution : L’assem ...
Ordinary general meeting
on 05-05-2017 at 12u · published 04-04-2017
Agenda
figure ci-dessous. ATTENTION Afin de permettre la présence du directeur financier de la Société lors de l’assemblée générale, le Conseil d’administration a décidé de tenir l’assemblée générale, à 12 heures, plutôt qu’à 9 heures comme le prévoit les statuts de la Société. Ordre du jour de l’assemblée générale ordinaire 1. Délibération sur le rapport annuel du conseil d’administration ayant trait à l’exercice social clôturé le 31 décembre 2016 et sur le rapport du commissaire ayant trait à l’exercice social clôturé le 31 décembre 2016. Commentaires sur ce point de l’ordre du jour : Le conseil d’adminis- tration prie l’assemblée générale des actionnaires de prendre note du rapport annuel du con ...
Extraordinary general meeting
on 09-05-2016 at 9u · published 07-04-2016
Agenda
figure ci-dessous. Ordre du jour de l’assemblée générale ordinaire 1. Délibération sur le rapport annuel du conseil d’administration ayant trait à l’exercice social clôturée le 31 décembre 2015 et sur le rapport du commissaire ayant trait à l’exercice social clôturé le 31 décembre 2015. Commentaires sur ce point de l’ordre du jour : Le conseil d’adminis- tration prie l’assemblée générale des actionnaires de prendre note du rapport annuel du conseil d’administration ayant trait à l’exercice social clôturé le 31 décembre 2015 et du rapport du commissaire ayant trait à l’exercice social clôturé le 31 décembre 2015. 2. Délibération sur le rapport de rémunération du conseil d’admi- nistration, co ...
Extraordinary general meeting
on 05-11-2015 at 11u · published 05-10-2015
Agenda
figure ci-dessous. Ordre du jour de l’assemblée générale extraordinaire 1. Approbation du plan de warrants 2015. Proposition de résolution : L’assemblée décide d’approuver le plan de warrants 2015,
Extraordinary general meeting
on 26-09-2013 at 17u · at the registered office · published 27-08-2013
figure ci-dessous. Si le quorum

We would like to set cookies. That happens only with your consent. What we measure